Pharmaceuticals
INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI
INOVIO and Richter-Helm BioLogics will expand existing DNA manufacturing agreement to support large-scale manufacturing of INO-4800 INO-4800 Phase 2/3 U.S. clinical trial being prepared to start this summer PLYMOUTH MEETING, Pennsylvania, April 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today ...
CPhI & P-MEC China to host 'Virtual Expo Connect' in June
SHANGHAI, April 30, 2020 /PRNewswire/ -- CPhI and P-MEC China -- co-organized by Informa Markets, CCCMHPIE and Sinoexpo Informa Markets -- will host a special Virtual Expo Connect in June (18-24, 2020). The new online platform is designed to facilitate ongoing and new business connections in an a...
WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform
SHANGHAI and HOUSTON, April 30, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Aravive, Inc. (NASDAQ:ARAV), a clinical-stage biopharmaceutical company, today announced a strategic collaboration agreement...
Alterity Therapeutics Limited Releases Its Appendix 4C - Q3 FY20 Quarterly Cash Flow Report
Highlights: * European Commission designated Orphan Drug status for ATH434's treatment of Multiple System Atrophy in the European Union * Phase 2 preparatory work continues * Cash balance of $10.4M MELBOURNE, Australia and SAN FRANCISCO, April 30, 2020 /PRNewswire/ -- Alterity Therapeutics ...
Fosun Pharma Invites Chinese and Foreign Experts to Jointly Discuss Prevention and Control Measures of COVID-19 Epidemic in Africa
SHANGHAI, April 29, 2020 /PRNewswire/ -- In order to support African medical institutions in their response to the COVID-19 pandemic, Fosun Pharma(Stock Code: 600196.SH, 02196.HK), partnering with Shanghai Fosun Foundation, Fosun Medical and Tridem Pharma, People's Daily Health platform and the H...
INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference
- INO-4700 (GLS-5300) DNA vaccine demonstrates 100% binding and 92% neutralizing antibody responses against MERS-CoV - INO-4800 DNA vaccine for COVID-19 currently in Phase 1 trial utilizes identical strategy targeting Spike protein and CELLECTRA intradermal delivery PLYMOUTH MEETING, Pennsylvani...
Gracell Reports Data of First-in-human Clinical Trial for Universal TruUCAR™ GC027 in Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Virtual Annual Meeting
SUZHOU, China and SHANGHAI, April 28, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell and gene therapy company, has announced data of its first-in-human clinical trial for UniversalTruUCAR™ GC027 in relapsed or refractory (R/R) T-cell acute lympho...
INOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June
INO-4800 Phase 2/3 U.S. clinical trial being prepared to start this summer Parallel preclinical challenge studies ongoing PLYMOUTH MEETING, Pa., April 28, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced that its Phase 1 U.S. clinical trial for COVID-19 DNA vaccine INO-4800 is fully enro...
PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitidepsin) for the Treatment of Patients With COVID-19
- The objective of the trial is to evaluate the efficacy and safety of plitidepsin in patients with COVID-19 requiring hospital admission - Plitidepsin recently obtained positive results from in vitro studies on the human HCoV-229E coronavirus, carried out at the National Biotechnology Center (C...
Insilico Medicine enters into a collaboration research with Astellas Pharma Inc. to apply novel generative artificial intelligence system for a conventionally challenging target family
TSUKUBA, Japan, April 28, 2020 /PRNewswire/ -- Insilico Medicine has announced that it has entered into a research collaboration agreement with Astellas Pharma Inc. to utilize Insilico Medicine's novel generative artificial intelligence technology aimed at accelerating development of candidates a...
Berkeley Lights Launches Two New Capabilities in the Opto Cell Therapy Development 1.0 Workflow to Accelerate the Creation Of Effective Cancer Immunotherapies
The new multiplex cytokine and cytotoxicity assays as a part of the Opto Cell Therapy Development 1.0 workflow will help users of the Berkeley Lights' platform develop cancer immunotherapies faster EMERYVILLE, Calif., April 28, 2020 /PRNewswire/ -- Today, Berkeley Lights, Inc., a leader in Digit...
Lianhua Qingwen Approved and Registered by Ministry of Public Health of Ecuador as Natural Medicine
SHIJIAZHUANG, China, April 27, 2020 /PRNewswire/ -- Yiling Pharmaceutical (002603.SZ) has obtained approval from the Ministry of Public Health ofEcuador for the sale and promotion of the Lianhua Qingwen Capsule (Granule) ("Lianhua Qingwen") in the country. The approval officially registers Lianhu...
Menarini Silicon Biosystems Explores New Application for Circulating Endothelial Cells in COVID-19
Enumeration of Circulating Endothelial Cells (CECs) with CELLSEARCH platform may offer a new tool for investigating the role of the damaged endothelium in SARS-CoV-2 infection and clinical manifestation BOLOGNA, Italy, April 27, 2020 /PRNewswire/ -- Menarini Silicon Biosystems, a global leader i...
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma
SHANGHAI, April 27, 2020 /PRNewswire/ -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on CARsgen's application for orphan designation of its...
Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate's International, Phase III Clinical Study
SHANGHAI, April 27, 2020 /PRNewswire/ -- On April 8, 2020, Shanghai Green Valley Pharmaceuticals,China received the formal decision letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the GV-971 international multi-center Phase III clinic...
AdaptVac Partners with AGC Biologics to Develop & Produce COVID-19 Vaccine
SEATTLE, April 24, 2020 /PRNewswire/ -- AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it is partnering with AdaptVac to develop and produce a COVID-19 vaccine. AdaptVac, together with its EU Horizon 2020 sponsored PREVENT-nCoV con...
Innovent and Eli Lilly Announce NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum as First-Line Therapy in Non-squamous NSCLC
SUZHOU, China, April 24, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jo...
First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany
STOCKHOLM, April 24, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, on 23rd April 2020, that the first patient in Germany is in treatment in the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac"). The first patient in Germany is in treatment...
Henlius receives EU GMP Certificate for HLX02 (Trastuzumab for Injection)
SHANGHAI, April 23, 2020 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company's drug substance (DS) line and drug product (DP) line for HLX02 trastuzumab biosimilar have successfully passed the European United (EU) Good Manufacturing Practice (GMP) on-site inspectio...
Lianhua Qingwen Listed in the Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme for Laos
SHIJIAZHUANG, China, April 22, 2020 /PRNewswire/ -- Yiling Pharmaceutical (002603.SZ) announced that Lianhua Qingwen capsules (granules) have been added to the "Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme forLaos" (Trial Version II) as the fourth traditional Chinese medicine to tre...
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00